Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBT Margin: 2017-2025

Historic EBT Margin for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -519.23%.

  • Arcus Biosciences' EBT Margin fell 32756.00% to -519.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -180.00%, marking a year-over-year decrease of 7772.00%. This contributed to the annual value of -109.30% for FY2024, which is 14796.00% up from last year.
  • Per Arcus Biosciences' latest filing, its EBT Margin stood at -519.23% for Q3 2025, which was down 29.81% from -400.00% recorded in Q1 2025.
  • In the past 5 years, Arcus Biosciences' EBT Margin ranged from a high of 79.39% in Q4 2021 and a low of -824.17% during Q3 2021.
  • For the 3-year period, Arcus Biosciences' EBT Margin averaged around -275.07%, with its median value being -256.62% (2023).
  • Data for Arcus Biosciences' EBT Margin shows a peak YoY increase of 177,268bps (in 2021) and a maximum YoY decrease of 82,700bps (in 2021) over the last 5 years.
  • Arcus Biosciences' EBT Margin (Quarterly) stood at 79.39% in 2021, then crashed by 27,645bps to -197.06% in 2022, then slumped by 6,101bps to -258.06% in 2023, then plummeted by 9,963bps to -357.69% in 2024, then plummeted by 32,756bps to -519.23% in 2025.
  • Its last three reported values are -519.23% in Q3 2025, -400.00% for Q1 2025, and -357.69% during Q4 2024.